Skip to main content

Gov. Whitmer Announces Pfizer Investing $750 Million to Expand U.S. Sterile Injectable Facility, Create 300 Jobs

FOR IMMEDIATE RELEASE 

December 5, 2022 

Contact: press@michigan.gov  

 

Gov. Whitmer Announces Pfizer Investing $750 Million to Expand U.S. Sterile Injectable Facility, Create 300 Jobs  

Investment further establishes the Kalamazoo, MI site as one of the most technologically advanced science facilities in the world, expanding access to Pfizer’s breakthrough medicines.  

 

LANSING, Mich. – Today Governor Gretchen Whitmer announced that Pfizer Inc. will be investing $750 million in its Kalamazoo, Michigan facility, expanding production and creating 300 good-paying jobs. This investment aims to establish the facility as one of the most technologically advanced in the world and continue to ensure the uninterrupted supply of Pfizer medicines and vaccines. This investment builds upon their initial investment of $465 million in the Kalamazoo facility and a $120 million expansion announced earlier this year. 

  

“Today, Pfizer is making another bold bet on Michigan’s manufacturing strengths and hardworking people,” said Governor Whitmer. “This $750 million investment will expand capacity at their Kalamazoo facility, creating good-paying jobs and fostering long-term economic opportunity for Michiganders. We brought this investment home thanks to effective collaboration between the state and Pfizer, and I know that Michigan’s future is bright because we have world-leading companies, economic momentum, and the hardest working people on the planet to move us forward.” 

  

One of Pfizer’s largest plants, the Kalamazoo facility is a global supplier of sterile injectable, liquid, and semi-solid medicines, as well as active pharmaceutical ingredients, producing more than 144 products. Currently, the multi-story, 400,000-square-foot MAP production facility employs 3,000 colleagues and contractors. Pfizer’s operations in Kalamazoo County generate an estimated annual economic impact in west Michigan of $3 billion. The plant has been in operation since 1948 and has had a presence in the community through the legacy Upjohn Company since 1886.  

  

“Since 2017, Pfizer has invested $5 billion to support the ongoing growth of our manufacturing leadership in the U.S.” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “This expansion is part of our blueprint to grow our U.S. manufacturing base, create more manufacturing jobs, and help ensure patients everywhere can get the medicines they need.” 

  

The MAP facility advances sterile manufacturing technology by placing products into distinct modules.  MAP phase 2 will incorporate technologically advanced aseptic manufacturing equipment, systems, and design, including multiple self-contained modular manufacturing lines. Proposed products in MAP 2 will utilize new mRNA technology and ultra-low temperature storage. 

  

“At Pfizer, we continue to invest in our manufacturing infrastructure, building a more resilient supply chain so patients have the medicines and vaccines they need,” said Mike McDermott, Chief Global Supply Officer, Executive Vice President, Pfizer. “This latest investment in our Kalamazoo site will help us advance some of the most innovative manufacturing technologies in sterile injectable production and distribution, while increasing access to these vital medicines.  The innovations we put into place in response to the pandemic are now part of our everyday ways of working. We are proud to be a leader in U.S. manufacturing and proud of the impact we have on patients and people around the world.”  

 

Gov. Whitmer speaks at podium during Pfizer announcement

 

Gov. Whitmer speaks at podium during Pfizer announcement

 

Representative from Pfizer speaks at podium during event

 

To learn more about Pfizer’s manufacturing and global supply, visit https://www.pfizer.com/products/how-drugs-are-made/global-supply or https://www.pfizer.com/about/careers  

  

*Ernst & Young (Company filings, company website, Evaluate Pharma, Research reports, Capital IQ, Secondary research, EY analysis – Data insights as of YE 2021) 

 

About Pfizer: Breakthroughs That Change Patients’ Lives  At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer

 

Disclosure Notice: 

The information contained in this release is as of December 5, 2022. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

 

This release contains forward-looking information about Pfizer manufacturing and Pfizer’s Kalamazoo, Michigan manufacturing site, including a planned investment in the Kalamazoo manufacturing site, supply of medicines and vaccines and their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development; risks related to the ability to realize the anticipated benefits of the investment and the manufacturing site; other business effects, including the effects of industry, market, economic, political or regulatory conditions; the impact of COVID-19 on our business, operations and financial results; and competitive developments.

 

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

 

Pfizer:  Media Relations  +1 (212) 733-1226  PfizerMediaRelations@pfizer.com 

 

Investor Relations  +1 (212) 733-4848  IR@pfizer.com 

Source: Pfizer Inc.